Literature DB >> 21446702

Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.

Kalyan Das1, Joseph D Bauman, Angela S Rim, Chhaya Dharia, Arthur D Clark, María-José Camarasa, Jan Balzarini, Eddy Arnold.   

Abstract

tert-Butyldimethylsilyl-spiroaminooxathioledioxide (TSAO) compounds have an embedded thymidine-analogue backbone; however, TSAO compounds invoke non-nucleoside RT inhibitor (NNRTI) resistance mutations. Our crystal structure of RT:7 (TSAO-T) complex shows that 7 binds inside the NNRTI-binding pocket, assuming a "dragon" shape, and interacts extensively with almost all the pocket residues. The structure also explains the structure-activity relationships and resistance data for TSAO compounds. The binding of 7 causes hyper-expansion of the pocket and significant rearrangement of RT subdomains. This nonoptimal complex formation is apparently responsible (1) for the lower stability of a RT (p66/p51) dimer and (2) for the lower potency of 7 despite of its extensive interactions with RT. However, the HIV-1 RT:7 structure reveals novel design features such as (1) interactions with the conserved Tyr183 from the YMDD-motif and (2) a possible way for an NNRTI to reach the polymerase active site that may be exploited in designing new NNRTIs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446702      PMCID: PMC3361896          DOI: 10.1021/jm101536x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  51 in total

1.  HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; L Vrang; J Walbers; H Zhang; B Oberg; A M Vandamme; M J Camarasa; E De Clercq
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

2.  Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; M J Camarasa; W G Tarpley; E De Clercq
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

3.  TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl 3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) purine and purine-modified nucleosides.

Authors:  S Velázquez; A San-Félix; M J Pérez-Pérez; J Balzarini; E De Clercq; M J Camarasa
Journal:  J Med Chem       Date:  1993-10-29       Impact factor: 7.446

4.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

5.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

6.  Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; M J Camarasa; E De Clercq
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

7.  2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

Authors:  J Balzarini; M J Pérez-Pérez; A San-Félix; D Schols; C F Perno; A M Vandamme; M J Camarasa; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

8.  3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.

Authors:  M J Camarasa; M J Pérez-Pérez; A San-Félix; J Balzarini; E De Clercq
Journal:  J Med Chem       Date:  1992-07-24       Impact factor: 7.446

9.  TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.

Authors:  M J Pérez-Pérez; A San-Félix; J Balzarini; E De Clercq; M J Camarasa
Journal:  J Med Chem       Date:  1992-08-07       Impact factor: 7.446

10.  1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.

Authors:  R Alvarez; S Velázquez; A San-Félix; S Aquaro; E De Clercq; C F Perno; A Karlsson; J Balzarini; M J Camarasa
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

View more
  16 in total

1.  An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.

Authors:  Nicholas Pagano; Peter Teriete; Margrith E Mattmann; Li Yang; Beth A Snyder; Zhaohui Cai; Marintha L Heil; Nicholas D P Cosford
Journal:  Bioorg Med Chem       Date:  2017-04-08       Impact factor: 3.641

2.  Peptides Mimicking the β7/β8 Loop of HIV-1 Reverse Transcriptase p51 as "Hotspot-Targeted" Dimerization Inhibitors.

Authors:  Pedro A Sánchez-Murcia; Sonia de Castro; Carlos García-Aparicio; M Angeles Jiménez; Angela Corona; Enzo Tramontano; Nicolas Sluis-Cremer; Luis Menéndez-Arias; Sonsoles Velázquez; Federico Gago; María-José Camarasa
Journal:  ACS Med Chem Lett       Date:  2020-01-24       Impact factor: 4.345

3.  Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ.

Authors:  Christal D Sohl; Michal R Szymanski; Andrea C Mislak; Christie K Shumate; Sheida Amiralaei; Raymond F Schinazi; Karen S Anderson; Y Whitney Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

4.  Examining the role of the HIV-1 reverse transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybrids.

Authors:  Suhman Chung; Jennifer T Miller; Mikalai Lapkouski; Lan Tian; Wei Yang; Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2013-04-17       Impact factor: 5.157

Review 5.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

6.  Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.

Authors:  Richard A Stanton; James H Nettles; Raymond F Schinazi
Journal:  J Mol Model       Date:  2015-10-08       Impact factor: 1.810

7.  Biochemical mechanism of HIV-1 resistance to rilpivirine.

Authors:  Kamalendra Singh; Bruno Marchand; Devendra K Rai; Bechan Sharma; Eleftherios Michailidis; Emily M Ryan; Kayla B Matzek; Maxwell D Leslie; Ariel N Hagedorn; Zhe Li; Pieter R Norden; Atsuko Hachiya; Michael A Parniak; Hong-Tao Xu; Mark A Wainberg; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-09-06       Impact factor: 5.157

8.  A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.

Authors:  Barry C Johnson; Gary T Pauly; Ganesha Rai; Disha Patel; Joseph D Bauman; Heather L Baker; Kalyan Das; Joel P Schneider; David J Maloney; Eddy Arnold; Craig J Thomas; Stephen H Hughes
Journal:  Retrovirology       Date:  2012-12-05       Impact factor: 4.602

9.  Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.

Authors:  Steven J Smith; Gary T Pauly; Aamir Akram; Kevin Melody; Ganesha Rai; David J Maloney; Zandrea Ambrose; Craig J Thomas; Joel T Schneider; Stephen H Hughes
Journal:  Retrovirology       Date:  2016-02-16       Impact factor: 4.602

Review 10.  Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.

Authors:  Lucianna Helene Santos; Rafaela Salgado Ferreira; Ernesto Raúl Caffarena
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.